Table 2 Potential therapeutic interventions and effects on targets of inflammatory network
From: NF-κB pathway activators as potential ageing biomarkers: targets for new therapeutic strategies
Therapies | Target effects |
|---|---|
Monoclonal antibodies against these cytokines and their receptors | Reduction of levels of IL-6, TNF-α |
Non-steroidal anti-inflammatory drug | |
Agonists of cytokine receptors or PRR receptors for people who do not respond to (or comply with) NSAID therapy | |
Antibody-mediated stimulation of the decoy TLR receptors, such as TAM receptors, or of the intracellular TLR regulators for people with pro-inflammatory alleles in TLR4 and TLR2 genes | |
Statin therapy | |
Physical activity | |
Administration of prebiotics and probiotics | |
Caloric restriction | Decrease of oxidative stress |
Polyphenols | |
Use of drugs having mimic CR action | |
Caloric restriction | Mitochondria biogenesis as preventive action against mitochondrial dysfunction |
Use of drugs having mimic CR action | |
Polyphenols | |
Caloric restriction | Reduction of the activation of NF-KB pathway |
Terpenoids | |
Resveratrol | |
Use of specific miRNAs | |
Administration of prebiotics and probiotics | |
Use of drugs having mimic CR action Curcumin | |
Caloric restriction: inhibition of mTOR pathway | Preventive action on the possible reduced activity of autophagic cleansing |
Rapamycin: inhibition of mTOR pathway | |
Curcumin: influences the mTOR pathway | |
Caloric restriction | Reduction of the excessive activation of Insulin/IGF1 pathway |
Metformin with CR mimic response |